Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38374188)

  • 1. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.
    Kim JY; Kim J; Kim YI; Yang DH; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
    Sci Rep; 2024 Feb; 14(1):4047. PubMed ID: 38374188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells.
    Watanabe H; Fujishima F; Unno M; Sasano H; Suzuki T
    Pathol Res Pract; 2023 Apr; 244():154418. PubMed ID: 36989844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic Impact of Peptide Hormonal Expression in Rectal Neuroendocrine Tumors.
    Kim J; Yang DH; Jung H; Cho H; Jang HJ; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
    Arch Pathol Lab Med; 2023 Jul; 147(7):797-807. PubMed ID: 36191342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors.
    Kim HS; Lee HS; Kim WH
    Cancer Res Treat; 2011 Sep; 43(3):181-8. PubMed ID: 22022296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
    Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
    Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors.
    Watanabe H; Fujishima F; Komoto I; Imamura M; Hijioka S; Hara K; Yatabe Y; Kudo A; Masui T; Tsuchikawa T; Sakamoto K; Shiga H; Nakamura T; Nakaya N; Motoi F; Unno M; Sasano H
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors.
    Fotouhi O; Zedenius J; Höög A; Juhlin CC
    Neuro Endocrinol Lett; 2018 Oct; 39(4):305-309. PubMed ID: 30531706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
    van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
    Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.
    Sherman SK; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
    Surgery; 2013 Dec; 154(6):1206-13; discussion 1214. PubMed ID: 24238043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
    Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
    Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer Prognosis.
    Kim J; Kim JY; Oh EH; Yoo C; Park IJ; Yang DH; Ryoo BY; Ryu JS; Hong SM
    Am J Surg Pathol; 2020 Nov; 44(11):1496-1505. PubMed ID: 32735108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
    Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.